FOLFOX方案联合西妥昔单抗治疗转移性结直肠癌的近期疗效及安全性分析

目的：探讨FOLFOX方案联合西妥昔单抗治疗转移性结直肠癌的近期临床疗效及安全性。方法：选择2009年2月～2011年2月本院诊治的42例转移性结直肠癌患者为研究对象，采用随机数字表法将其随机分入对照组与观察组，其中对照组20例，观察组22例。对照组患者接受FOLFOX方案治疗，每2周重复1次，治疗3周期；观察组患者给予FOLFOX方案联合西妥昔单抗治疗。比较两组的近期疗效及毒副反应。结果：观察组的客观缓解率和疾病控制率均显著高于对照组，差别具有统计学意义（P〈0．05）；骨髓抑制、消化道反应、神经毒性是两组常见的毒副反应，两组患者骨髓抑制、消化道反应、神经毒性、脱发及肝功能损害发生率无显著差别（P〉0．05），观察组痤疮样皮疹的发生率显著高于对照组（36．4％VS0，P〈0．05）。结论：西妥昔单抗联合FOLFOX方案可提高转移性结直肠癌患者的近期疗效，毒副反应可耐受。

Short Term Effect and Security of FOLFOX Regimen Combined with Cetuximab in the Treatment of Metastatic Colorectal Cancer

Objective： To explore the short term effect and security of FOLFOX regimen combined with cetuximab in the treat- ment of metastatic colorectal cancer. Methods： 42 cases with metastatic colorectal cancer hospitalized from February 2009 to February 2011 were selected. And randomly divided into the control group （20 cases） and observation group （22 cases） according to the random number table, the control group was given FOLFOX regimen treatment and the observation group received FOLFOX regimen combined with cetuximab therapy. The chemotherapy was repeated every 2 weeks, with a total of 3 cycles. The short term effect and security were compared between two groups. Results： The objective remission rate and disease control rate in experience group were much higher than those in the control group （P〈0.05）. Myelosuppression, gastrointestinal reaction and neurotoxicity were the main toxic and side effects in two groups. There was no significant difference of incidence rate of myelosuppression, gastrointestinal reaction, neurotoxicity, alopecia and liver function damage between two groups. The incidence rate of exanthems in experience group was significantly higher than that in the control group （36.4% vs 0, P〈0.05）. Conclusion： The clinical efficacy of FOLFOX regimen combined with cetuximab was better than that of FOLFOX regimen alone in the treatment of metastatic colorectal cancer, and the toxicity could be well tolerated.